✦ LIBER ✦

Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group

✍ Scribed by Peter Forsyth; Greg Cairncross; David Stewart; Michael Goodyear; Nancy Wainman; Elisabeth Eisenhauer

Publisher: Springer US
Year: 1996
Tongue: English
Weight: 330 KB
Volume: 14
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00210791

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of trimetrexate in malign

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

✍ Neill A. Iscoe; Elizabeth A. Eisenhauer; Audley J. Bodurtha 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 183 KB

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxic

Phase II study of flutamide in patients

Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study

✍ Daniele J. Perrault; Diane M. Logan; David J. Stewart; Vivien H. C. Bramwell; Al 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 271 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer. Eight patients had received no prior systemic therapy for their metastatic disease and 13 had only one site of metastasis.

Gemcitabine, dexamethasone, and cisplati

Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma : A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)

✍ Michael Crump; Tara Baetz; Stephen Couban; Andrew Belch; Deborah Marcellus; Kang 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

Molecular predictors of outcome in a pha

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer : National Cancer Institute of Canada Clinical Trials Group Study PA.3

✍ Gilda da Cunha Santos; Neesha Dhani; Dongsheng Tu; Kayu Chin; Olga Ludkovski; Su 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 311 KB 👁 3 views

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati

Phase II trial of gemcitabine and doceta

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Judith Manola; Daniel J. Schneider; John F. Schwerkoske; Christo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

## Abstract ## BACKGROUND Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemothera